1.915

0.30% 0.005

Century Therapeutics Inc (IPSC)

Overview News Price History Option Chain Financials Discussions Forecast

Century Therapeutics Inc stock is traded at $1.915, with a volume of 245.99K. It is up +0.30% in the last 24 hours and down -14.41% over the past month. Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Previous Close:

$1.92

Open:

$1.92

24h Volume:

245.99K

Relative Volume:

0.20

Market Cap:

$346.76M

Revenue:

$109.16M

Net Income/Loss:

$-107.78M

P/E Ratio:

-1.731

EPS:

-1.1063

Net Cash Flow:

$-95.45M

1W Performance:

-2.74%

1M Performance:

-14.41%

6M Performance:

-0.22%

1Y Performance:

+242.79%

1-Day Range:

$1.89

$1.95

1-Week Range:

$1.89

$2.0875

52-Week Range:

$0.435

$3.04

Century Therapeutics Inc Stock (IPSC) Company Profile

Name

Century Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

215-981-4000

Address

25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

IPSC's Discussions on Twitter

Compare IPSC vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IPSC Century Therapeutics Inc	1.915	347.66M	109.16M	-107.78M	-95.45M	-1.1063
VRTX Vertex Pharmaceuticals Inc	515.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.22	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.16	39.31B	5.76B	514.49M	1.10B	4.4813

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	TD Cowen	Buy
Aug-08-24	Initiated	Rodman & Renshaw	Buy
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Dec-27-22	Initiated	Chardan Capital Markets	Buy
Oct-31-22	Initiated	Guggenheim	Buy
Oct-10-22	Initiated	Canaccord Genuity	Buy
May-23-22	Initiated	H.C. Wainwright	Buy
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	BofA Securities	Buy
Jul-13-21	Initiated	JP Morgan	Overweight
Jul-13-21	Initiated	Piper Sandler	Overweight

View All

Century Therapeutics Inc Stock (IPSC) Latest News

01:17 AM

HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat

01:17 AM

Aug 13, 2026

TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo

Aug 13, 2026

Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Aug 12, 2026

Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat

Aug 12, 2026

Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media

Aug 12, 2026

Form 8K Century Therapeutics Inc For: 12 August - Investing.com India

Aug 12, 2026

Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks

Aug 12, 2026

Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada

Aug 12, 2026

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times

Aug 12, 2026

Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029 - Quiver Quantitative

Aug 12, 2026

Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary - TradingView

Aug 12, 2026

Century Therapeutics Q2 net loss misses estimates on lease termination loss - TradingView

Aug 12, 2026

Century Therapeutics (IPSC) books $34.6M loss but holds $197M cash - Stock Titan

Aug 12, 2026

FDA and Century Align on Type 1 Diabetes Therapy Trial Plan - Stock Titan

Aug 12, 2026

Aug 07, 2026

We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Moomoo

Aug 07, 2026

Aug 06, 2026

Century Therapeutics (IPSC) Projected to Announce Earnings on Thursday - MarketBeat

Aug 06, 2026

Aug 05, 2026

Century Therapeutics (IPSC) SVP has automatic share sale to cover RSU taxes - Stock Titan

Aug 05, 2026

Aug 02, 2026

Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC - MarketBeat

Aug 02, 2026

DV Trading LLC Makes New Investment in Century Therapeutics, Inc. $IPSC - MarketBeat

Aug 02, 2026

Jul 31, 2026

Century Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Jul 31, 2026

Jul 27, 2026